Lung cancer is the leading cause of cancer death worldwide, accounting for more deaths
than breast, prostate and colon cancer combined. While treatment decisions are determined …

The new International Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society lung adenocarcinoma classification provides, for the …

Since the 2015 WHO classification was introduced into clinical practice,
immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second …

Immunohistochemistry has recently emerged as a powerful ancillary tool for differentiating
lung adenocarcinoma and squamous cell carcinoma—a distinction with important …

Purpose: There is persistent controversy as to whether EGFR and KRAS mutations occur in
pulmonary squamous cell carcinoma (SQCC). We hypothesized that the reported variability …

Immunohistochemistry is increasingly utilized to differentiate lung adenocarcinoma and
squamous cell carcinoma. However, detailed analysis of coexpression profiles of commonly …

The last decade has seen significant advances in our understanding of lung cancer biology
and management. Identification of key driver events in lung carcinogenesis has contributed …

Abstract p53 mutations, occurring in two-thirds of all human cancers, confer a gain of
function phenotype, including the ability to form metastasis, the determining feature in the …

Abstract Background Tumor protein 63 (p63) is a transcription factor of the p53 gene family
involved in differentiation of several tissues including squamous epithelium. p63 …